Prognostic values of baseline cortisol levels and neutrophil to lymphocyte ratio in COVID-19
Prognostic values of baseline cortisol in COVID-19
Abstract
Background: The prediction of disease severity in COVID-19 is valuable for providing appropriate supportive care earlier and reducing mortality. We aimed to evaluate the impact of baseline cortisol values on disease severity and assess the correlation between the neutrophil to lymphocyte ratio (NLR) and cortisol levels.
Methods: In this retrospective study, we compared the prognostic value of baseline the NLR, morning cortisol, ferritin, and C-reactive protein (CRP) levels among patients with severe and nonsevere COVID-19. The relationships were assessed with Spearman’s correlation.
Results: Of 167 patients, 63 (37.7%) had severe disease, and their baseline cortisol levels were higher than those in the nonsevere group (18.92 µg/dL vs 13.8 µg/dL, p=0.011). The baseline cortisol level and NLR had area under the curve (AUC) values of 0.62 (95% confidence interval [CI] 0.53-0.71) and 0.70 (CI 95% 0.62-0.78) for the prediction of severe COVID-19, respectively. Severe disease was predicted in patients with a baseline cortisol cutoff ≥ 18.92 µg/dL (552 nmol/L) with a specificity of 75.0%, a sensitivity of 50.79%. The cutoff value for the NLR on day 1 was ≥ 6.2, with a specificity of 93.27% and a sensitivity of 32.79%. Baseline cortisol levels showed a significant weak-moderate positive correlation with the NLR and levels of CRP and ferritin on day 1 (r=0.33, r= 0.29, r= 0.28, respectively, p<0.001 for all).
Conclusions: The baseline cortisol level in COVID-19 patients is a good predictive marker for disease severity and non-inferior to the NLR. However, it is inferior to CRP and ferritin.
References
2. World Health Organization, Clinical management of COVID-19, Interim guidance. https://www.who.int/publications/i/item/clinical-management-of-covid-19. Updated May 27, 2020.
3. Huang I, Pranata R, Lim MA, Oehadian A, and Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937175.
4. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206.
5. Lian J, Jin C, Hao S, Zhang X, Yang M, Jin X, et al. High neutrophil-to-lymphocyte ratio associated with progression to critical illness in older patients with COVID-19: a multicenter retrospective study. Aging (Albany NY). 2020;12(14):13849-59.
6. Li X, Liu C, Mao Z, Xiao M, Wang L, Qi S, et al. Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Crit Care. 2020;24(1):647.
7. Panesar NS. Lymphopenia in SARS. Lancet. 2003;361(9373):1985.
8. Panesar NS. What caused lymphopenia in SARS and how reliable is the lymphokine status in glucocorticoid-treated patients? Med Hypotheses. 2008;71(2):298-301.
9. Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31(4 Suppl): S253-7.
10. Tan T, Khoo B, Mills EG, Phylactou M, Patel B, Eng PC, et al. Association between high serum total cortisol concentrations and mortality from COVID-19. Lancet Diabetes Endocrinol. 2020;8(8):659-60.
11. . National Institutes of Health (NIH). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Clinical Spectrum of SARS-CoV-2 Infection. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Updated December 17, 2020.
12. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13.
Copyright (c) 2022 Buket Erturk Sengel, Elif Tukenmez Tigen, Can Ilgin, Volkan Korten, Zekaver Odabasi
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.